Recent Updates
Recently added Catalysts
EOLS Positive Sentiment

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Wednesday, August 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Evolus, Inc. reported strong financial results for the second quarter of 2026, highlighting significant growth in its injectable aesthetics portfolio. The company achieved its third consecutive quarter of positive adjusted EBITDA, driven by double-digit growth for Jeuveau® and increased adoption of Evolysse®. Evolus raised its full-year financial outlook due to this momentum.

Market Sentiment Analysis

POSITIVE FACTORS

  • Evolus reported strong financial results for Q2 2026.
  • The company achieved its third consecutive quarter of positive adjusted EBITDA.
  • Evolus is gaining significant market share in injectable aesthetics.
  • There is double-digit growth for Jeuveau® and increasing adoption of Evolysse®.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~12 mo
Medium dilution risk
Lead asset
PrabotulinumtoxinA-Xvfs
Phase 2 · Glabellar Frown Lines

Full Press Release Details

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the second quarter ended June 30, 2026. “The increasing momentum of our portfolio focus has resulted in Evolus gaining significant share across injectable aesthetics during the second quarter, supported by double-digit growth for Jeuveau® and accelerating adoption of Evolysse®,” said

Frequently Asked Questions

What were Evolus' financial results for Q2 2026?

Evolus reported strong financial results for the second quarter of 2026.

How many consecutive quarters of positive EBITDA has Evolus achieved?

Evolus has achieved three consecutive quarters of positive adjusted EBITDA.

What products contributed to Evolus' growth?

Double-digit growth for Jeuveau® and increasing adoption of Evolysse® contributed to Evolus' growth.

Did Evolus raise its financial outlook for 2026?

Yes, Evolus raised its full-year financial outlook due to positive momentum.

ShareAdd on Google
Tags: EOLS Viatris Investor Conferences Healthcare Evolus financial results injectable aesthetics Q2 2026
Last updated: Aug 5, 2026

Biotech snapshot

Cash runway
$50M liquidity · $3M/mo burn
~12 mo
Medium dilution risk
Lead asset
PrabotulinumtoxinA-XvfsPhase 2
Glabellar Frown Lines →